Switching to ixazomib-based induction feasible, effective in newly diagnosed multiple myeloma
12 Dec 2019
byStephen Padilla
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Switching to ixazomib-based induction feasible, effective in newly diagnosed multiple myeloma
12 Dec 2019